FDA advisers vote against Biogen's Alzheimer's drug, leaving its future in doubt

The fate of what was poised to be the first drug approved to treat the underlying cause of Alzheimer's disease is now less certain, following a contentious Friday meeting of an expert committee convened by the Food and Drug Administration to debate the experimental medicine.